Patients undergoing endovascular repair of thoracic aneurysms can receive the clinical benefits of Cook Medical's novel Zenith TX2 TAA Endovascular Graft with Pro-Form for more controlled treatment of thoracic aortic aneurysms (TAAs). Cook's novel TX2 Pro-Form endograft, which has received CE Mark approval, utilizes an improved delivery system that allows for carefully controlled deployment of the endograft to help ensure proximal conformity of the device to the aortic wall. This innovation offers patients unparalleled safety in endovascular TAA repair, even for procedures where endografts have to be positioned in what physicians consider to be uncommonly tight aortic arches, which are notoriously difficult to properly seal. In approximately 25 per cent of TAA patients, the aortic arch, which is formed like a reversed U, is exceptionally tight. Many currently available endografts are too rigid or have sealing stents that lack the radial force to conform correctly to the inner curvature of these tight arches, so that the graft does not seal off the aneurysm properly. As a consequence, surgeons in the past have been forced to remodel the arch with a balloon or use other aids to position the graft to reduce the risk of continued bleeding into the aneurysm and possible rupture, thus making the repair procedure longer and more complex. With the TX2 Pro-Form's enhanced delivery system, these measures are no longer necessary. Patients receive a potentially safer, more effective procedure, and physicians have a more efficient and controllable treatment option due to the reduced procedural time that the TX2 graft with Pro-Form permits. Prof. Ralf Kolvenbach at the Augusta Hospital and Catholic Clinics in Düesseldorf and a Professor at the University of Düsseldorf is the first vascular surgeon to have repaired a TAA with the TX2 Pro-Form. “Using the TX2 Pro-Form I was able to seal the patient's thoracic aneurysm in minimal time and with maximum control. The stent's new delivery system enabled me to place the graft to the precise location desired and fit it perfectly to the walls of blood vessel,” Prof. Kolvenbach explained. “With this stent graft system we have reached a new level of safety in thoracic aortic aneurysm repair.” Phil Nowell explains: “Our aim is to provide surgeons with the best technology to treat patients with the greatest degree of control available in the industry. Through continuous product advancement in partnership with some of the world's leading vascular surgeons, we are thrilled to introduce this industry-leading advance in treating thoracic abdominal aneurysms. Many physicians are familiar with the relatively common problem of thoracic endografts forming a “bird's beak” gap along its underside when the graft is deployed into a tight aortic arch. We believe this improvement is a significant leap toward the solution of that problem.”